<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03822364</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-009-101</org_study_id>
    <nct_id>NCT03822364</nct_id>
  </id_info>
  <brief_title>Staccato Apomorphine Single and Multi Dose PK</brief_title>
  <official_title>A Randomized Study of the Safety, Tolerability, and Pharmacokinetics of AZ-009 (Staccato Apomorphine) in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZ-009 in Subjects With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in 3 parts. A) compare the pharmacokinetics (PK) of a single
      dose of AZ-009 with that of a therapeutically-relevant dose of a commercially available
      apomorphine injector in healthy volunteers; B) ascending doses of active drug in healthy
      volunteers; and C) examine the tolerability, safety, and PK of AZ-009 in subjects with
      established Parkinson's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in 3 parts. Parts A and B will be conducted in healthy
      volunteers and Part C will be conducted in subjects with established Parkinson's disease. The
      primary objectives for each part are as follows.

      Part A: To compare the pharmacokinetics of a single low dose of AZ-009 with that of a
      therapeutically-relevant dose a commercially available apomorphine injector in healthy
      volunteers.

      Part B: To examine the tolerability and safety of AZ-009 of single ascending doses of active
      drug in healthy volunteers while; and to characterize the pharmacokinetics of single
      ascending doses of AZ-009 in healthy volunteers

      Part C: To examine the tolerability, safety, and pharmacokinetics of AZ-009 in subjects with
      established Parkinson's disease and to identify optimal doses to bring into multiple
      ascending dose safety and efficacy studies; and to assess the usability of AZ-009 in subjects
      with Parkinson's Disease
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 26, 2018</start_date>
  <completion_date type="Actual">March 26, 2019</completion_date>
  <primary_completion_date type="Actual">March 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A 3 part study including: A) Single Dose Crossover in Healthy Volunteers, B) Single Ascending Dose with placebo control in Healthy Volunteers, and C) Single Ascending Dose with placebo control in Subjects with Established Parkinson's Disease</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A-Relative bioavailability of inhaled Staccato apomorphine dose compared to the subcutaneous administration</measure>
    <time_frame>24 hours</time_frame>
    <description>Relative bioavailability of inhaled Staccato apomorphine compared to active comparator injection based on the Geometric Least Squares Mean Ratio of AUCinf for all subjects completing the crossover part of the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>B-Dose Proportionality by Power Analysis of AUCinf</measure>
    <time_frame>24 hours</time_frame>
    <description>Dose proportionality of inhaled Staccato apomorphine AUCinf across all doses administered in the single ascending dose portions of the study (Parts B and C) using a power model [regression of log(AUCinf) versus log(dose)]</description>
  </primary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>A-1 (009-1 -&gt; active comparator)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Arm 1 (Inhaled apomorphine, Dose 1 followed by commercially available active comparator)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A-2 (active comparator -&gt; 009-1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Arm 2 (commercially available active comparator followed by Inhaled apomorphine, Dose 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-1a (009-2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B, Arm 1 (Inhaled apomorphine, Dose 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-1p (009-0)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part B, Arm 1 (Inhaled placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-2a (009-3)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part B, Arm 2 (Inhaled apomorphine, Dose 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-2p (009-0)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part B, Arm 2 (Inhaled placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-3a (009-4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B, Arm 3 (Inhaled apomorphine, Dose 4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-3p (009-0)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part B, Arm 3 (Inhaled placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-1a (009-3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C, Arm 1 (Inhaled apomorphine, Dose 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-1p (009-0)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part C, Arm 1 (Inhaled placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-2a (009-4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C, Arm 2 (Inhaled apomorphine, Dose 4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-2p (009-0)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part C, Arm 2 (Inhaled placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-3a (009-5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C, Arm 3 (Inhaled apomorphine, Dose 5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-3p (009-0)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part C, Arm 3 (Inhaled placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>009-1</intervention_name>
    <description>Inhaled apomorphine via Staccato aerosol, Dose 1</description>
    <arm_group_label>A-1 (009-1 -&gt; active comparator)</arm_group_label>
    <arm_group_label>A-2 (active comparator -&gt; 009-1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>active comparator</intervention_name>
    <description>commercially available apomorphine injector</description>
    <arm_group_label>A-1 (009-1 -&gt; active comparator)</arm_group_label>
    <arm_group_label>A-2 (active comparator -&gt; 009-1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>009-0</intervention_name>
    <description>Inhaled placebo via Staccato device</description>
    <arm_group_label>B-1p (009-0)</arm_group_label>
    <arm_group_label>B-2p (009-0)</arm_group_label>
    <arm_group_label>B-3p (009-0)</arm_group_label>
    <arm_group_label>C-1p (009-0)</arm_group_label>
    <arm_group_label>C-2p (009-0)</arm_group_label>
    <arm_group_label>C-3p (009-0)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>009-2</intervention_name>
    <description>Inhaled apomorphine via Staccato aerosol, Dose 2</description>
    <arm_group_label>B-1a (009-2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>009-3</intervention_name>
    <description>Inhaled apomorphine via Staccato aerosol, Dose 3</description>
    <arm_group_label>B-2a (009-3)</arm_group_label>
    <arm_group_label>C-1a (009-3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>009-4</intervention_name>
    <description>Inhaled apomorphine via Staccato aerosol, Dose 4</description>
    <arm_group_label>B-3a (009-4)</arm_group_label>
    <arm_group_label>C-2a (009-4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>009-5</intervention_name>
    <description>Inhaled apomorphine via Staccato aerosol, Dose 5</description>
    <arm_group_label>C-3a (009-5)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males and females between 18 and 60 years of age, inclusive at the time
             of signing the informed consent document.

          -  Body weight â‰¥ 50 kg and BMI within the range of 18 to 32 kg/m2.

          -  Willing and able to be confined at the clinical research center for the study period
             and adhere to overall study visit schedule, procedures and other protocol
             requirements.

          -  Understand and voluntarily sign an informed consent document prior to any study
             related assessments/procedures being conducted.

        Exclusion Criteria:

          -  Any significant medical condition, psychiatric illness or history of depression that
             could, in the investigator's opinion, compromise the subject's safety or interfere
             with the completion of this protocol.

          -  History of clinically significant central nervous system, cardiac, pulmonary,
             metabolic, renal, hepatic, or gastrointestinal conditions including gastric bypass or
             other weight loss surgical procedure; or history of such conditions that, in the
             opinion of the investigator, may place the subject at an unacceptable risk as a
             participant in this trial.

          -  Use of non-prescription medications within 5 days prior to the first dose of study
             drug.

          -  Use of medication that is inhibitor or inducer of CYP450-3A4/5 within 3 days of
             dosing.

          -  Consumption of grapefruit, grapefruit juice, star fruit, oranges, orange juice,
             Seville oranges, within 3 days prior to administration of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert J Groeneveld, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Human Drug Research (The Netherlands)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <zip>2333 CL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apomorphine</keyword>
  <keyword>aerosol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

